VARILRIX
Description
VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) is a live-attenuated varicella vaccine which contains the Oka-strain of the attenuated varicella-zoster virus.
VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) is indicated for:
the active immunization against varicella of healthy subjects from 12 months of age and up.
the active immunization against varicella of susceptible high risk patients and their susceptible healthy close contacts.
Immunization Guideline
Children (12 months to 12 years of age, inclusive) should receive 2 doses (0.5 mL each) of VARILRIX® to ensure optimal protection against varicella with a minimum interval of 6 weeks between doses.
Adolescents and adults (13 years of age and older) should receive two 0.5 mL doses with a minimum interval of 6 weeks between doses.
For high risk patients additional doses of vaccine may be required.
Administration
VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) should be administered by subcutaneous injection in the deltoid region. VARILRIX® must not be administered intravascularly or intradermally.
Additional information
Contraindications
Contraindicated in subjects having shown signs of hypersensitivity after a previous administration of varicella vaccine dose, including anaphylactic reaction, subjects with known hypersensitivity to neomycin or any component of the vaccine. A history of contact dermatitis to neomycin is not a contraindication. The administration of VARILRIX should be postponed in subjects suffering from acute severe febrile illness. In healthy subjects the presence of a minor infection, however, is not a contraindication for vaccination.
country-of-manufacture
Belgium
manufacturer
GlaxoSmithKline
package-size
1 Dose
pharmaceutical-form
Lyophilized
preservative
None
route-of-administration
Subcutaneous
vaccine-type
chickenpox